Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy
CTR20254711Phase 3Active
- Sponsor
- argenx
- Start
- Dec 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of efgartigimod alfa + hyaluronidase-qvfc in Autoimmune Myopathies, sponsored by argenx. Started Dec 2025; status: active.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on CTR20254711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254711.